Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1661-1668

  Shao, Shan ^a   Li, Su ^a   Qin, Youwen ^a   Wang, Xiaorui ^a   Yang, Yining ^a   Bai, Haitao ^a   Zhou, Lili ^a   Zhao, Chuxian ^a   Wang, Chun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

AKT; Autophagy; Chronic myeloid leukemia; GSK3 ; Imatinib mesylate; Spautin 1

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; SPAUTIN 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; K 562 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BENZAMIDES; BENZYLAMINES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PIPERAZINES; PYRIMIDINES; QUINAZOLINES;

EID: 84899091326     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2313     Document Type: Article

References (30)

1. Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR and McKenna SL: Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol 88: 455-462, 2013.
2. Cortez D, Reuther G and Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342, 1997. (Pubitemid 27496983)
3. Yang X, Lin J, Gong Y, et al: Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol 30: 123-130, 2012.
4. Carew JS, Nawrocki ST, Giles FJ and Cleveland JL: Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2: 201-204, 2008.
5. Burchert A: Roots of imatinib resistance: a question of self-renewal? Drug Resist Updat 10: 152-161, 2007.
6. Yang ZJ, Chee CE, Huang S and Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10: 1533-1541, 2011.
7. Yu Y, Yang L, Zhao M, et al: Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 26: 1752-1760, 2012.
8. Bellodi C, Lidonnici MR, Hamilton A, et al: Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119: 1109-1123, 2009.
9. Crowley LC, Elzinga BM, O'Sullivan GC and McKenna SL: Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol 86: 38-47, 2011.
10. Liu J, Xia H, Kim M, et al: Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147: 223-234, 2011.
11. Zhao M, Yang M, Yang L, et al: HMGB1 regulates autophagy through increasing transcriptional activities of JNK and ERK in human myeloid leukemia cells. BMB Rep 44: 601-606, 2011.
12. Salomoni P and Calabretta B: Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy 5: 1050-1051, 2009.
13. Mishima Y, Terui Y, Taniyama A, et al: Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 99: 2200-2208, 2008.
14. Yu Y, Cao L, Yang L, Kang R, Lotze M and Tang D: microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 8: 853-855, 2012.
15. Sheng Z, Ma L, Sun JE, Zhu LJ and Green MR: BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 118: 2840-2848, 2011.
16. Tong Y, Liu YY, You LS and Qian WB: Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin 33: 542-550, 2012.
17. Burchert A, Wang Y, Cai D, et al: Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782, 2005. (Pubitemid 41486155)
18. Frame S, Cohen P and Biondi RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327, 2001. (Pubitemid 32607364)
19. Linke R and Dempke W: Management of imatinib-resistant CML patients. Onkologie 30: 574-580, 2007. (Pubitemid 350085279)
20. Drullion C, Tregoat C, Lagarde V, et al: Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis 3: e373, 2012.
21. Drullion C, Lagarde V, Gioia R, et al: Mycophenolic acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leuk Res Treatment 2012: 861301, 2012.
22. Yue Z, Jin S, Yang C, Levine AJ and Heintz N: Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 100: 15077-15082, 2003. (Pubitemid 37518019)
23. Han W, Sun J, Feng L, et al: Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One 6: e28491, 2011.
24. Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N and Taniwaki M: Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. Curr Cancer Drug Targets 13: 69-79, 2013.
25. McCubrey JA, Steelman LS, Abrams SL, et al: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722, 2008. (Pubitemid 351565619)
26. McCubrey JA, Steelman LS, Bertrand FE, et al: Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 28: 15-33, 2014.
27. Chiara F and Rasola A: GSK-3 and mitochondria in cancer cells. Front Oncol 3: 16, 2013.
28. Maurer U, Charvet C, Wagman AS, Dejardin E and Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760, 2006. (Pubitemid 43376126)
29. Morel C, Carlson SM, White FM and Davis RJ: Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 29: 3845-3852, 2009.
30. Wang R, Xia L, Gabrilove J, Waxman S and Jing Y: Downregulation of Mcl-1 through GSK-3beta activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 27: 315-324, 2013.